Los Angeles, CA, United States of America

Michael Torgov

USPTO Granted Patents = 49 (Patent Applications = 12)

CIPO Patents = 7 (Patent Applications = 3)

EPO Patents = 10 (Patent Applications = 17)

Average Co-Inventor Count = 5.2

ph-index = 8

Forward Citations = 360(Granted Patents)

Location History:

Hamden, CT (US) (2010)
Middletown, CT (US) (2014)
San Francisco, CA (US) (2015 - 2017)
Los Angeles, CA (US) (2016 - 2021)
Santa Monica, CA (US) (2013 - 2023)
Redondo Beach, CA (US) (2022 - 2024)

Company Filing History:

19 out of 40

Abbvie Stemcentrx LLC

Seattle Genetics, Inc.

patents

5. 5 out of 7

Tae Life Sciences, LLC

Celldex Therapeutics Limited

where one patent can have more than one assignee

Years Active: 2010-2025

Loading Chart...

49 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12319707 - Dosage unit form(s) comprising BTS and BTS(OMe) for use in boron neutron capture therapy and methods thereof (2025-06-03),

2. 12139503 - Borylated amino acid compositions for use in boron neutron capture therapy and methods thereof (2024-11-12),

3. 11884688 - Borylated amino acid compositions comprising BTS and BTS(OMe) for use in boron neutron capture therapy and methods thereof (2024-01-30),

4. 11566031 - Borylated amino acid compositions for use in boron neutron capture therapy and methods thereof (2023-01-31),

5. 11559582 - Antibody drug conjugates (ADC) that bind to 191P4D12 proteins (2023-01-24),

6. 11219689 - Boron enriched linker ('BEL') compositions for boron neutron capture therapy and methods thereof (2022-01-11),

7. 11033634 - Light chain variable regions (2021-06-15),

8. 10894090 - Antibody drug conjugates (ADC) that bind to 191P4D12 proteins (2021-01-19),

9. RE48389 - Antibody drug conjugates (ADC) that bind to 191P4D12 proteins (2021-01-11),

10. 10533051 - Anti SEZ6 antibodies and methods of use (2020-01-14),

11. 10478509 - Anti-DLL3 antibody drug conjugates for treating cancer (2019-11-19),

12. 10137204 - Anti-DLL3 antibody drug conjugates for treating cancer (2018-11-27),

13. 9968687 - Anti-DLL3 antibody drug conjugates (2018-05-15),

14. 9962454 - Antibody drug conjugates (ADC) that bind to 191P4D12 proteins (2018-05-08),

15. 9937268 - Anti-DLL3 antibody drug conjugates and methods of use (2018-04-10),

Title: Michael Torgov: Innovator in Biomedicine

Introduction

Michael Torgov is an accomplished inventor based in Los Angeles, CA, known for his significant contributions to the field of biomedicine. With an impressive portfolio of 34 patents, he has focused on developing innovative modulators that improve treatment options for proliferative disorders.

Latest Patents

Among Torgov's latest patents are two notable innovations. The first is a patent for light chain variable regions, which includes novel modulators, such as antibodies and their derivatives, aimed at treating proliferative disorders. The second patent relates to anti-seizure related 6 (SEZ6) antibodies and their applications, providing new avenues for therapeutic intervention in similar medical conditions.

Career Highlights

Throughout his career, Michael Torgov has made a mark in several esteemed companies, including AbbVie and Stemcentrx, Inc. His work at these organizations has contributed to advancements in biopharmaceuticals and molecular therapeutics, enhancing treatment methodologies in critical health areas.

Collaborations

Torgov has collaborated with notable experts, including Orit Foord and Robert A. Stull. These partnerships have enriched his research and fostered innovation, further illustrating the importance of collaboration in advancing medical technology.

Conclusion

Michael Torgov stands out as an influential inventor in the realm of biomedicine, with a robust number of patents to his name. His persistent dedication to discovering and developing therapeutic solutions has significantly impacted the treatment of proliferative disorders. Through his collaborations and work with leading companies, Torgov continues to pave the way for future innovations in medicine.

This text is generated by artificial intelligence and may not be accurate.